All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis.
| Molecular Weight | 503.33 |
| CAS Number | 951395-08-7 |
| Storage | 2-8°C, dry, sealed |
[1] No authors listed. Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
| Related Transthyretin (TTR) Products |
|---|
| Tafamidis
Tafamidis is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade, with EC50s of 2.7-3.2 μM to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR. |
| A 1120
A 1120 is a high-affinity antagonist of retinol-binding protein 4 (RBP4) with a Ki value of 8.3 nM that disrupts the interaction between RBP4 and its conjugate transthyretin. |
| Acoramidis hydrochloride
Acoramidis (AG10) hydrochloride is an orally active, selective stabilizer of the thyroxine transporter (TTR (transthyretin)) that is effective against both wild-type and V1221 mutant types. Acoramidis (AG10) hydrochloride can be used for the study of transthyroxine amyloidosis. |
| Acoramidis
Acoramidis (AG10) is an orally active, selective stabilizer of the thyroxine transporter (TTR) that is effective against both wild-type and V1221 mutant types. |
| WT-TTR inhibitor 1
WT-TTR inhibitor 1 is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
